MESIMA FAQ
MESIMA FAQ
No. While many products claim to use Sanghwang (Phellinus linteus), only the product branded as "Mesima"—developed by Korea New Pharmaceuticals in collaboration with KRIBB—is backed by over a decade of research under Korea's G7 national project. It uses the Phellinus linteus yoo strain, genetically verified and closely related to ATCC 26710, and is the only one approved as a prescription drug.
Many so-called Mesima products are merely powdered mycelium or fruiting bodies lacking standardization, clinical validation, or regulatory approval. Only Korea New Pharmaceuticals' Mesima contains the purified proteoglycan extract processed with proprietary technology ensuring consistent efficacy and safety.
Yes. Mesima supports a broad-spectrum, nonspecific immunotherapy mechanism. Rather than targeting specific cancer cells, it activates multiple immune effector pathways—macrophages, T cells, NK cells—enhancing the body's ability to recognize and suppress malignant growth regardless of tumor origin.
This makes it suitable as a supportive therapy across multiple cancer types including gastrointestinal, hepatic, breast, and even hematologic malignancies.
In late-stage cases, Mesima has demonstrated efficacy in alleviating chemotherapy side effects, improving immune function, and maintaining patient quality of life. While tumor regression may be limited by disease progression, Mesima contributes to better tolerability and longer survival when used in parallel with standard therapies.
Clinicians report reduced nausea, appetite loss, fatigue, and cancer-related pain in patients regularly taking Mesima during treatment.
Yes. Due to its immunomodulatory mechanism, Mesima may benefit conditions linked to immune dysregulation. Preclinical studies indicate activity in type 1 diabetes, while anecdotal evidence suggests potential support in autoimmune diseases such as rheumatoid arthritis and myasthenia gravis.
Ongoing patent filings also include claims for HIV/AIDS immune support, reinforcing its classification as a broad-spectrum immune response modulator (BRM).
Mesima is classified as nontoxic based on rigorous safety testing conducted by the Korea Institute of Chemical Technology, a GLP-certified research body. Clinical studies and real-world use indicate excellent safety with rare occurrences of mild gastrointestinal symptoms such as diarrhea, easily mitigated with probiotic supplementation.
Yes. Mesima is frequently used concurrently with chemotherapy or conventional treatments in clinical settings. It not only shows no interaction risks, but also enhances therapeutic outcomes by mitigating cytotoxic drug side effects.
There is currently no known contraindication with prescription or over-the-counter medications, nor with other health supplements.
Mesima is best taken continuously, particularly in oncology applications. Since cancer represents a systemic immune dysfunction, prolonged use is advisable to maintain surveillance and immune readiness against recurrence or progression.
For preventative health, long-term consumption can support immune balance and resilience in high-risk populations.